Zachary A Bornholdt
Overview
Explore the profile of Zachary A Bornholdt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen C, Balinandi S, Kuehne A, Rock M, Bonagofski L, Ricks K, et al.
J Infect Dis
. 2024 Sep;
PMID: 39248523
Evaluating the adaptive immune responses to natural infection with Crimean-Congo hemorrhagic fever (CCHF) virus (CCHFV) in human survivors is critical to the development of medical countermeasures. However, the correlates of...
2.
Wirchnianski A, Nyakatura E, Herbert A, Kuehne A, Abbasi S, Florez C, et al.
PLoS Pathog
. 2024 Apr;
20(4):e1012134.
PMID: 38603762
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated...
3.
Kuang E, Cross R, McCavitt-Malvido M, Abelson D, Borisevich V, Stuart L, et al.
Pathogens
. 2022 Jun;
11(6).
PMID: 35745509
Intravenous (IV) administration of antiviral monoclonal antibodies (mAbs) can be challenging, particularly during an ongoing epidemic, due to the considerable resources required for performing infusions. An ebolavirus therapeutic administered via...
4.
Cross R, Bornholdt Z, Prasad A, Woolsey C, Borisevich V, Agans K, et al.
JCI Insight
. 2022 Apr;
7(10).
PMID: 35413016
A major challenge in managing acute viral infections is ameliorating disease when treatment is delayed. Previously, we reported the success of a 2-pronged mAb and antiviral remdesivir therapeutic approach to...
5.
Mittler E, Wec A, Tynell J, Guardado-Calvo P, Wigren-Bystrom J, Polanco L, et al.
Sci Transl Med
. 2022 Mar;
14(636):eabl5399.
PMID: 35294259
The rodent-borne hantavirus Puumala virus (PUUV) and related agents cause hemorrhagic fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (ANDV) and Sin Nombre virus, cause a...
6.
Haslwanter D, Lasso G, Wec A, Furtado N, Raphael L, Tse A, et al.
Cell Host Microbe
. 2022 Jan;
30(2):248-259.e6.
PMID: 34998466
The resurgence of yellow fever in South America has prompted vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a live-attenuated YF-17D virus derived from...
7.
Mishra A, Hellert J, Freitas N, Guardado-Calvo P, Haouz A, Fels J, et al.
Science
. 2021 Nov;
375(6576):104-109.
PMID: 34793197
Crimean-Congo hemorrhagic fever virus (CCHFV) is the most widespread tick-borne zoonotic virus, with a 30% case fatality rate in humans. Structural information is lacking in regard to the CCHFV membrane...
8.
Doyle M, Kose N, Borisevich V, Binshtein E, Amaya M, Nagel M, et al.
Cell Rep
. 2021 Sep;
36(9):109628.
PMID: 34469726
Hendra virus and Nipah virus (NiV), members of the Henipavirus (HNV) genus, are zoonotic paramyxoviruses known to cause severe disease across six mammalian orders, including humans. We isolated a panel...
9.
Fels J, Maurer D, Herbert A, Wirchnianski A, Vergnolle O, Cross R, et al.
Cell
. 2021 Jun;
184(13):3486-3501.e21.
PMID: 34077751
Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific treatments and vaccines are urgently needed. Here,...
10.
Dang H, Cross R, Borisevich V, Bornholdt Z, West B, Chan Y, et al.
Nat Struct Mol Biol
. 2021 Apr;
28(5):426-434.
PMID: 33927387
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses (HNVs) causing respiratory illness and severe encephalitis in humans, with fatality rates of 50-100%. There are no licensed therapeutics or vaccines...